耐万古霉素屎肠球菌对奎奴普丁-达福普汀与其他抗菌药物联合使用的协同性测试。
Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents.
作者信息
Matsumura S O, Louie L, Louie M, Simor A E
机构信息
Department of Microbiology, SD Laboratory Services, Sunnybrook and Women's College Health Sciences Centre, North York, Canada.
出版信息
Antimicrob Agents Chemother. 1999 Nov;43(11):2776-9. doi: 10.1128/AAC.43.11.2776.
Abstract
Using checkerboard and time-kill assays, we evaluated the in vitro activity of quinupristin-dalfopristin (RP 59500) alone and in combination with five other antimicrobial agents against 12 clinical strains of vancomycin-resistant Enterococcus faecium (VREF). In time-kill studies, six VREF strains exhibited synergism with the combination of quinupristin-dalfopristin and doxycycline and three exhibited synergism with quinupristin-dalfopristin plus ampicillin-sulbactam. Combinations of quinupristin-dalfopristin with these and other agents warrant further clinical evaluation for the treatment of serious VREF infections.
摘要
我们采用棋盘法和时间杀菌试验，评估了单独使用喹奴普丁-达福普汀（RP 59500）以及将其与其他五种抗菌药物联合使用时，对12株耐万古霉素屎肠球菌（VREF）临床菌株的体外活性。在时间杀菌研究中，6株VREF菌株对喹奴普丁-达福普汀与强力霉素的联合用药表现出协同作用，3株对喹奴普丁-达福普汀加氨苄西林-舒巴坦表现出协同作用。喹奴普丁-达福普汀与这些及其他药物的联合用药，值得进一步进行临床评估，以用于治疗严重的VREF感染。
相似文献
1
Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents.
Antimicrob Agents Chemother. 1999 Nov;43(11):2776-9. doi: 10.1128/AAC.43.11.2776.
2
Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations.
Antimicrob Agents Chemother. 1998 Oct;42(10):2710-7. doi: 10.1128/AAC.42.10.2710.
3
Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort.
J Antimicrob Chemother. 1997 May;39 Suppl A:145-51. doi: 10.1093/jac/39.suppl_1.145.
4
Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium.
Diagn Microbiol Infect Dis. 1996 Jul;25(3):127-31. doi: 10.1016/s0732-8893(96)00123-x.
5
Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci.
Antimicrob Agents Chemother. 2002 May;46(5):1319-24. doi: 10.1128/AAC.46.5.1319-1324.2002.
6
The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group.
J Antimicrob Chemother. 1999 Aug;44(2):251-61. doi: 10.1093/jac/44.2.251.
7
Treatment options for vancomycin-resistant enterococcal infections.
Drugs. 2002;62(3):425-41. doi: 10.2165/00003495-200262030-00002.
8
In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
J Antimicrob Chemother. 1997 May;39 Suppl A:33-9. doi: 10.1093/jac/39.suppl_1.33.
9
Quinupristin/Dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium.
Clin Infect Dis. 2000 May;30(5):790-7. doi: 10.1086/313766. Epub 2000 May 18.
10
Synergic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium.
J Antimicrob Chemother. 1997 May;39 Suppl A:63-6. doi: 10.1093/jac/39.suppl_1.63.
引用本文的文献
1
Uncovering the Important Genetic Factors for Growth during Cefotaxime-Gentamicin Combination Treatment in Encoding .
Antibiotics (Basel). 2023 Jun 1;12(6):993. doi: 10.3390/antibiotics12060993.
2
Synergistic Action of AMX Associated with 1,8-Cineole and Its Effect on the ESBL Enzymatic Resistance Mechanism.
Antibiotics (Basel). 2022 Jul 26;11(8):1002. doi: 10.3390/antibiotics11081002.
3
When does 2 plus 2 equal 5? A review of antimicrobial synergy testing.
J Clin Microbiol. 2014 Dec;52(12):4124-8. doi: 10.1128/JCM.01121-14. Epub 2014 Jun 11.
4
Successful treatment of a neonate with persistent vancomycin-resistant enterococcal bacteremia with a daptomycin-containing regimen.
Infect Drug Resist. 2008;1:9-11. doi: 10.2147/idr.s3649. Epub 2008 Aug 12.
5
In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.
Antimicrob Agents Chemother. 2002 Aug;46(8):2606-12. doi: 10.1128/AAC.46.8.2606-2612.2002.
6
Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci.
Antimicrob Agents Chemother. 2002 May;46(5):1319-24. doi: 10.1128/AAC.46.5.1319-1324.2002.
7
Treatment options for vancomycin-resistant enterococcal infections.
Drugs. 2002;62(3):425-41. doi: 10.2165/00003495-200262030-00002.
8
Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline.
Antimicrob Agents Chemother. 2001 Nov;45(11):3202-4. doi: 10.1128/AAC.45.11.3202-3204.2001.
本文引用的文献
1
Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination.
Clin Infect Dis. 1998 Dec;27(6):1554-6. doi: 10.1086/517755.
2
Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations.
Antimicrob Agents Chemother. 1998 Oct;42(10):2710-7. doi: 10.1128/AAC.42.10.2710.
3
Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin.
Antimicrob Agents Chemother. 1998 May;42(5):1088-92. doi: 10.1128/AAC.42.5.1088.
4
In vitro activity of chloramphenicol alone and in combination with vancomycin, ampicillin, or RP 59500 (quinupristin/dalfopristin) against vancomycin-resistant enterococci.
Diagn Microbiol Infect Dis. 1997 Nov;29(3):203-5. doi: 10.1016/s0732-8893(97)81811-1.
5
In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium.
Antimicrob Agents Chemother. 1997 Nov;41(11):2573-5. doi: 10.1128/AAC.41.11.2573.
6
Species identification of enterococci via intergenic ribosomal PCR.
J Clin Microbiol. 1997 May;35(5):1054-60. doi: 10.1128/jcm.35.5.1054-1060.1997.
7
Ampicillin plus ciprofloxacin therapy of experimental endocarditis caused by multidrug-resistant Enterococcus faecium.
J Antimicrob Chemother. 1995 Jul;36(1):253-8. doi: 10.1093/jac/36.1.253.
8
In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.
Antimicrob Agents Chemother. 1993 Mar;37(3):598-601. doi: 10.1128/AAC.37.3.598.
9
Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR.
J Clin Microbiol. 1995 Jan;33(1):24-7. doi: 10.1128/jcm.33.1.24-27.1995.
10
Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group.
Diagn Microbiol Infect Dis. 1995 Feb;21(2):85-93. doi: 10.1016/0732-8893(94)00147-o.
Zotero 插件